Despite advances in surgery, radiation and chemotherapy, the treatment of malignant brain tumors remains one of the most perplexing clinical areas with the fewest advances in treatment in the field of oncology. It is of central importance to determine treatment response or failure, for both patients and physicians. Currently, the effectiveness of therapy is monitored by MRI or CT scanning of the tumor, along with neurological assessment of the patient. These indicators are imperfect since changes in tumor volume can take months to appear on conventional imaging, and changes in neurological function are often unrelated to change in tumor growth and volume. Nevertheless, such measures of therapeutic response are currently relied upon to determine when a different treatment option should be pursued. The availability of earlier and more accurate predictive indicators of treatment response would have obvious benefit to individual patients, as well as to advancing the treatment of brain tumors generally by facilitating clinical trials of new agents. This application seeks to advance the use of quantitative MRI for the clinical evaluation of brain tumor patients by adding information related to cellular membrane integrity and vascular volume to the anatomical detail provided by conventional MRI. The proposal is based on promising recent MR data from rodent brain tumor models and preliminary studies of human brain tumors. These have shown that microscopic cellular changes occur in the tissue structure of brain tumors following successful treatment; moreover these occur before changes in tumor volume are manifest. Changes in tumor cellular structure were detected as an increase in the apparent mobility (diffusion) of water within the tumor tissue using a specialized diffusion-sensitive MRI acquisition and processing techniques. The observation of an increase in water diffusion is indicative of therapy-induced tumor necrosis that is manifest as cellular membrane breakdown and cell shrinkage. These events facilitate movement of water within an enlarged extracellular space. It is hypothesized the effectiveness of a treatment can be assessed before there is a reduction in tumor volume, because the rate of cellular breakdown and necrosis is relatively rapid compared with the process of resorption and removal of cellular debris. In addition, specialized MRI techniques allow the mapping tumor blood volume (TBV) and perfusion. We further hypothesize that treatment of brain tumors damages tumor vasculature, thereby decreasing vessel density and total blood volume within tumors responsive to therapy. We propose to initiate a clinical study to further test these hypotheses on brain tumor patients. Clinical and MRI data will be collected on 164 subjects accrued from two institutions, University of Michigan and University of Pittsburgh. Conventional MRI and quantitative images of diffusion, TBV and perfusion will be obtained in these patients prior to and following initiation of treatment with chemotherapy and/or irradiation. Changes in diffusion and blood flow parameters will be quantitated and correlated with later measurement of clinical outcomes via tumor volume change and patient survival in order to determine the predictive value of the quantitative MRI indicators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085878-02
Application #
6662788
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2002-09-01
Project End
2003-08-31
Budget Start
Budget End
Support Year
2
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Smith, Andrew; Pawar, Mercy; Van Dort, Marcian E et al. (2018) Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors. J Ocul Pharmacol Ther 34:477-485
Akgül, Seçkin; Li, Yinghua; Zheng, Siyuan et al. (2018) Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. Cell Rep 24:463-478.e5
Pal, Anupama; Rehemtulla, Alnawaz (2018) Imaging Proteolytic Activities in Mouse Models of Cancer. Methods Mol Biol 1731:247-260
Durmo, Faris; Lätt, Jimmy; Rydelius, Anna et al. (2018) Brain Tumor Characterization Using Multibiometric Evaluation of MRI. Tomography 4:14-25
Barthel, Floris P; Wei, Wei; Tang, Ming et al. (2017) Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet 49:349-357
Hu, Xin; Martinez-Ledesma, Emmanuel; Zheng, Siyuan et al. (2017) Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro Oncol 19:786-795
Nyati, Shyam; Young, Grant; Ross, Brian Dale et al. (2017) Quantitative and Dynamic Imaging of ATM Kinase Activity. Methods Mol Biol 1596:131-145
Galbán, Stefanie; Apfelbaum, April A; Espinoza, Carlos et al. (2017) A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis. Mol Cancer Ther 16:2340-2350
Yang, Dongzhi; Comeau, Anthony; Bowen, Wayne D et al. (2017) Design and Investigation of a [18F]-Labeled Benzamide Derivative as a High Affinity Dual Sigma Receptor Subtype Radioligand for Prostate Tumor Imaging. Mol Pharm 14:770-780
Martinez, Carlos H; Diaz, Alejandro A; Meldrum, Catherine et al. (2017) Age and Small Airway Imaging Abnormalities in Subjects with and without Airflow Obstruction in SPIROMICS. Am J Respir Crit Care Med 195:464-472

Showing the most recent 10 out of 170 publications